Third U.S. patent on Teva's MS drug Copaxone invalidated

NEW YORK (Reuters) - U.S. patent officials on Thursday invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after cancelling two other patents on the drug last week.